FIELD: biotechnology.
SUBSTANCE: invention relates to the field of preservation of biological material, in particular, to defrosting of cryopreserved cells or tissues. A defrosting solution contains, per 100 ml: 0.1-50 g of biomimetic material for suppression of ice growing, water-soluble saccharide at a concentration of 0-1.0 mol/l, and the rest is a buffer. Biomimetic material for suppression of ice growing is atactic polyvinyl alcohol (PVA) having syndiotacticity of 15-65%, molecular weight of 10-500 kDa, or a combination of the specified atactic polyvinyl alcohol (PVA), amino acid, polypeptide, and/or polyamino acid. Amino acid is selected from one of or a combination of two or more of arginine, threonine, proline, lysine, histidine, glutamine, aspartic acid, glycine. Polypeptide is one or more of L-Thr-L-Arg (TR), L-Thr-L-Pro (TP), L-Arg-L-Thr (RT), L-Pro-L-Thr (PT), L-Thr-L-Arg-L-Thr (TRT), L-Thr-L-Pro-L-Thr (TPT), or L-Thr-L-Cys-L-Thr (TCT). The defrosting solution is used in a defrosting reagent, which contains defrosting solutions I-IV, wherein defrosting solutions I-IV have different compositions by quantitative content of initial components.
EFFECT: proposed defrosting solution provides effective control of ice crystal growth, as well as significant reduction in cell or tissue damage caused by uncontrolled ice crystal growth during reduction, reduction in risks of a short service life and inclusion of parasitic biological contaminants to bonds with the absence in a composition of animal serum, contributes to preservation of stability, when passaging cells or tissues, has low toxicity.
10 cl, 4 dwg, 2 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
CRYOPRESERVING SOLUTION NOT CONTAINING DMSO AND ITS PRODUCTION METHOD AND USE | 2020 |
|
RU2785227C1 |
BIOMIMETIC MATERIAL SUPPRESSING ICE GROWTH AND CRYOPRESERVING SOLUTION CONTAINING THIS MATERIAL | 2020 |
|
RU2787934C1 |
STABLE PHARMACEUTICAL PREPARATION BASED ON THE PD-1 ANTIBODY AND ITS USE IN MEDICINE | 2016 |
|
RU2731418C2 |
METHOD OF VITRIFICATION OF OVARIAL TISSUE | 2018 |
|
RU2678106C2 |
PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
CATALYST COMPONENT FOR POLYMERIZATION OR COPOLYMERIZATION OF OLEFINS, METHOD OF ITS PREPARATION AND ITS USE | 2021 |
|
RU2809186C1 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO SOST, AND ITS USE | 2018 |
|
RU2779430C2 |
MACROPOROUS GEL MATERIAL AND BASED PRODUCTS | 2006 |
|
RU2328313C2 |
KERATIN BD-10, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2020 |
|
RU2823655C1 |
KERATIN BD-3, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2020 |
|
RU2815384C1 |
Authors
Dates
2023-03-06—Published
2020-03-02—Filed